SAN JOSE, Calif., May 14, 2026
Resurge Therapeutics announced positive clinical findings from two studies evaluating its proprietary IntraProstatic Drug Elution (IPDE) platform for the treatment of benign prostatic hyperplasia (BPH), highlighting the potential of the company’s office-based therapy to provide durable symptom relief for millions of men suffering from lower urinary tract symptoms (LUTS). The results, scheduled for presentation at the American Urological Association (AUA) 2026 Annual Meeting in Washington, D.C., demonstrated meaningful improvements in urinary symptoms, urinary flow rates, and prostate volume reduction with a favorable safety profile.
The IPDE platform is designed as a long-acting localized therapy that delivers paclitaxel-eluting bioabsorbable implants directly into the prostate, enabling targeted tissue remodeling while minimizing systemic drug exposure. Resurge Therapeutics believes the technology could represent a first-in-class minimally invasive treatment approach for BPH, potentially reducing dependence on chronic oral medications and invasive surgical procedures.
Clinical Studies Demonstrate Strong Symptom Relief
The company reported positive outcomes from both a transperineal dose escalation study and a separate transrectal feasibility study, evaluating the safety and effectiveness of the IPDE therapy in men with symptomatic BPH. Across both studies, patients experienced substantial improvements in urinary symptoms and urinary flow after receiving a single treatment administration.
In the transperineal study involving 20 patients, investigators observed an average improvement of 15 points in International Prostate Symptom Score (IPSS) one year after treatment. Maximum urinary flow rate (Qmax) improved by approximately 4 mL/s, while 80% of participants achieved clinically meaningful symptom relief. Researchers also reported no serious drug-related or procedure-related adverse events and no evidence of systemic drug toxicity.
Advertisement
The transrectal feasibility study demonstrated similarly encouraging results. Among 11 treated patients, mean IPSS improved by 15 points as early as one month after treatment and remained durable through at least six months. Investigators reported that 100% of patients achieved clinically significant symptom improvement, while urinary flow increased by 4.1 mL/s and prostate volume was reduced by 23% at six months.
Importantly, both studies showed that the procedures were well tolerated, with patients reporting minimal pain during discharge and only mild transient adverse events. No cases of de novo erectile dysfunction were observed, an important consideration in BPH treatment where sexual side effects frequently limit patient satisfaction with available therapies.
IPDE Platform Targets Limitations of Existing Therapies
Benign prostatic hyperplasia affects approximately 40 million men in the United States, making it one of the most common urological disorders among aging male populations. Current treatment options often rely on chronic oral medications or invasive surgical procedures, both of which may carry tolerability issues, adherence challenges, and long-term complications.
Resurge Therapeutics stated that its IPDE platform was specifically designed to address these limitations by delivering controlled localized drug therapy directly into enlarged prostate tissue through a single minimally invasive procedure. By concentrating therapeutic activity within the prostate while limiting systemic exposure, the technology aims to improve efficacy while reducing unwanted side effects commonly associated with oral BPH medications.
Company leadership believes the platform has the potential to shift BPH treatment earlier in the care pathway, providing patients with a durable alternative before disease progression necessitates surgical intervention. The company estimates the U.S. market opportunity for the IPDE platform could exceed $5 billion annually, reflecting the large patient population seeking more effective and convenient treatment options.
Resurge Advances Next Phase of Development
Following the positive findings, Resurge Therapeutics plans to advance the IPDE platform into larger randomized, double-blind, placebo-controlled clinical studies in both the United States and international markets. The company confirmed it is actively engaging with regulatory authorities and healthcare stakeholders to support the next phase of clinical development and future commercialization efforts.
Industry analysts continue to view localized drug delivery and minimally invasive urology technologies as rapidly expanding segments within the MedTech industry. As healthcare providers increasingly seek office-based therapies capable of delivering durable outcomes with reduced recovery times, Resurge Therapeutics believes the IPDE platform may help redefine future treatment strategies for benign prostatic hyperplasia and related urological disorders.
Source: Resurge Therapeutics press release
